May Lower RFR Signal Repeat Revascularization? - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

May Lower RFR Signal Repeat Revascularization?

Patients with lower nonischemic resting full-cycle ratio values had more repeat revascularizations despite similar 2-year major cardiovascular event rates.

  • By

  • Andrea Surnit

  • July 28, 2026

  • 4 min

Share

  • 1

    Deferring coronary revascularization based on nonischemic resting full-cycle ratio (RFR) may lead to favorable 2-year cardiovascular outcomes.

  • 2

    Patients with lower nonischemic RFR values underwent repeat revascularization more frequently compared to those with higher values.

  • 3

    The study evaluated 773 patients with 1,012 angiographically intermediate coronary lesions from 2016 to 2022.

  • 4

    At 2 years, the lesion-based major adverse cardiovascular event (MACE) rate was 8%, with no significant differences across RFR groups.

  • 5

    Chronic obstructive pulmonary disease was independently associated with higher rates of MACE following multivariable adjustment.

Original Source(s)

May Lower RFR Signal Repeat Revascularization?

  • by Andrea Surnit

  • July 28, 2026

Related Content

Case report: Additional Imaging Supports TAPVR Care

A case report shows that advanced cardiac CT and MRI imaging can improve surgical planning and reintervention for patients with infradiaphragmatic total anomalous pulmonary venous return (TAPVR). See what Sebastián Quiñones-Carrasquillo, MD, and co-authors Todd Nowlen, MD and Daniel Velez, MD, recommend for using these advanced diagnostic imaging modalities.

  • by

  • August 12, 2026

  • 6 min
Could Pregnancy Complications Predict CVD Risk?

Investigators found that adding pregnancy-related and female-specific factors modestly improved postpartum cardiovascular risk prediction compared with traditional risk factors alone.

Can Sugammadex Lower Postsurgical Pulmonary Complications?

A large international randomized trial found fewer postoperative pulmonary complications with sugammadex vs. neostigmine following major abdominal or thoracic surgery, although the difference was driven primarily by reduced atelectasis.